Register Now: Does Your Pharmaceutical WMS Grow with You?
News|Articles|July 26, 2024

Pharma Pulse 7/26/24: Talent Management Strategies for Post-Milestone Growth, Dispensing Medication for Muslims & more

The latest news for pharma industry insiders.

Talent Management Strategies for Post-Milestone Growth

Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives.

Dispensing Medication for Muslims: A Guide for Pharmacists

Despite Muslim patients’ need for halal medication, more than 80% of pharmacists were found to lack knowledge about where to look to find alternative medications that are halal.

AI Can Write Poetry, but It Struggles With Math

A.I.’s math problem reflects how much the new technology is a break with computing’s past.

European Commission Approves Pfizer’s DURVEQTIX

Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.

@fda on Threads

Do you have food safety questions as a result of a severe weather situation or power outage? You can find information on our website fda.gov/food… and you can call our food safety experts for help at 888-SAFE-FOOD. We're open Mon-Fri, 10 am - 4 pm ET.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.